Dr Lihua Zheng China

AnHeart Therapeutics is an oncology-focused clinical stage biopharmaceutical company headquartered in Hangzhou, China with offices in Beijing, Shanghai and New York. The company’s pipeline consists of three clinical stage assets: Taletrectinib, a next-gen ROS1 and NTRK inhibitor currently in Phase 2; an mIDH1 inhibitor ready for Phase 2 for low grade glioma, cholangiocarcinoma, AML and other tumors; and an AXL inhibitor in Phase 1 for overcoming resistance in various tumors.
Company Size (Fulltime employees)
Year of foundation
2018
Please specify your partnering goal
1/Funding Raising for Series B; 2/Pipeline Asset EU and Korea out licensing; 3/In licensing new clinical PoC oncology assets
Headquartner in China
Assets Information 1
Taletrectinib|next-gen ROS1/NTRK inhibitor, the leading program, currently in a Phase 2 trial in China and ex-China global trials to start in early 2021|ROS1+ NSCLC|Global
Assets Information 2
AB-218/DS-1001|a potentially best-in-class mIDH-1 inhibitor in co-development with Daiichi Sankyo (Japan rights), to start with ex-Japan global Phase 2 trials in glioma and conduct preclinical and clinical POC studies in other indications|IDH1+ Lower Grade Glioma|ex-Japan
Assets Information 3
AB-329/DS-1205|a potentially best-in-class AXL inhibitor, to start with preclinical and clinical POC studies in multiple indications|combo with PD-1 ab for NSCLC|Global
Biotech/Pharma Asset Stage
Dr Lihua Zheng
AnHeart Therapeutics
LinkedIn logo CBO & co-Founder 
Functionality

Linda Zheng China

A French PHARMA & cosmetics company
Partnering Objectives
Headquartner in China
Biotech/Pharma Category
Pierre Fabre Medicament China
Senior Market Access & Health Economics Director 

Jia Zhilong China

a large hospital
Partnering Objectives
Headquartner in China
Chinese PLA general hospital
assistant professor 

Sandra Zhong China

Suzhou Kintor Pharmaceuticals, Inc.
BD Director 

Bella Zhou China

戴德梁行 国际五大行之一
Website:
Cushman.com
Partnering Objectives
Headquartner in China
Cushman
Associate director 

yanfei zhou China

ZhongXi Capital focus on biomedical investment,fiancing,consulting and other capital market business.
Website:
Partnering Objectives
Headquartner in China
ZhongXi Capital
高级投资经理 

sylvie zhou China

license-in paradigm shifting durgs to China patients
Website:
Www.lianbio.com
Partnering Objectives
Headquartner in China
lianbio
Sr director 

ping zhou China

Website:
www.jitri.org
Partnering Objectives
Headquartner in China
江苏省产业技术研究院
senior business manager 

Ivy Zhou China

Shenzhen Beimei Pharma is focused in the field of pediatric prescription drugs, and aims to become a new-styled pharmaceutical company integrated with R&D, in-licensing, production and sales. It takes independent R&D and the in-licensing of domestic and international pediatric products as its strategic direction. The current product pipeline covers the respiratory, anti-infection (antibacterial), neuroscience, gastroenterology and others. Beimei Pharma is committed to providing Chinese pediatric patients with convenient, accurate, excellent-taste and high-quality products.
Partnering Objectives
Headquartner in China
Shenzhen Beimei Pharmaceutical Co. Ltd.
Head of Business Development 

Monica Zhou China

Established in Shenzhen Special Economic Zone in 1992;
Core competitiveness - A specialty company in digestion and intestinal microecology and a national level Hi-tech Enterprise.
Partnering Objectives
Headquartner in China
Biotech/Pharma Category
Shenzhen Wanhe Pharma
BD